Teva Pharmaceutical Industries Ltd. and other generic drugmakers have held talks with the US Justice Department in the past six months about resolving a long-running criminal antitrust probe of alleged price-fixing by the companies, according to people familiar with the matter.
Among the possible outcomes that have been discussed are deferred prosecution agreements in which the companies would admit to certain allegations but would be shielded from indictment in exchange for cooperating with the investigation and paying fines.
Talks are being held with drugmakers individually, and any one or all of the negotiations could fail to result in an agreement,